PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -11.68% and 11.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?